27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
Sino-American company Brii Biosciences has announced positive data from the ACTIV-2 Phase III trial evaluating the combination of BRII-196 and BRII-198 in non-hospitalized COVID-19 patients. 26 August 2021
Pharma major Eli Lilly is expanding its portfolio in the field of targeted protein degradation forging a research and licensing deal with fellow USA-based biotech firm Lycia Therapeutics. 26 August 2021
Servier Pharmaceuticals, the US subsidiary of French drugmaker Servier, has won approval for Tibsovo (ivosidenib) in cholangiocarcinoma, a rare and aggressive form of cancer. 26 August 2021
US drugmaker Eagle Pharmaceuticals has entered into a worldwide licensing agreement with Swiss biotech Combioxin for the commercial rights to CAL02, an antitoxin agent ready for Phase IIb/III development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. 26 August 2021
Bain Capital has sold its 42.9%-plus convertible bonds in Kosdaq-listed botulinum toxin maker Hugel, reported the Korea JoongAng Daily and other media. 26 August 2021
A month ahead of the expected decision date, the US Food and Drug Administration yesterday approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH), says Danish biotech Ascendis Pharma. 26 August 2021
Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically-significant improvement in daily mean copper mobilization from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments 26 August 2021
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an update to its cost-effectiveness model for therapies in hereditary angioedema (HAE). 25 August 2021
A Texan biotech company focused on Alzheimer’s disease saw its share price slip by 24% during Wednesday morning’s trading after claims were posted about the firm’s scientific integrity online on Tuesday after market hours. 25 August 2021
The European Commission (EC) has approved Rinvoq (upadacitinib), an oral, selective and reversible JAK inhibitor from US pharma major AbbVie, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. 25 August 2021
The International Vaccine Institute (IVI) has announced the first participant received Bharat Biotech International Ltd’s (BBIL) Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica. 25 August 2021
Research from industry analyst GlobalData suggests that HIV drugs containing tenofovir alafenamide (TAF) are set to book sales over $15 billion by the year 2029. 25 August 2021
For spinal muscular atrophy (SMA) Awareness Month, we take a look at advances in the pharmacological treatment of this rare hereditary disease. 25 August 2021
Approval has been granted for the combination of Opdivo (nivolumab) intravenous infusion and Cabometyx (cabozantinib s-malate) tablets in Japan for the treatment of unresectable or metastatic renal cell carcinoma (RCC), for a partial change in approved items of the manufacturing and marketing approval. 25 August 2021
India's Council of Scientific and Industrial Research (CSIR)'s constituent Central Drug Research Institute (CDRI) has teamed up with domestic drugmaker Marc Laboratories to develop a compound for treating heart attack and stroke. 25 August 2021
UK-based T cell receptor (TCR) biotech firm Immunocore yesterday announced that regulators in the USA and European Union have each accepted applications for the approval of tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma (mUM). 25 August 2021
The Russian Ministry of Health spent more than 26.1 billion roubles ($351 million) on the procurements of drugs against HIV this year, an increase of 10% compared with the year earlier, according to recent statements by Ministry’s press-service, reports The Pharma Letter’s local correspondent. 25 August 2021
The city of St Petersburg will retain its status as one of the leading centers of pharmaceutical production in Russia, due to the almost doubling of revenue of pharmaceutical companies operating their facilities within the territory of the city this year. 25 August 2021
Children in England are set to be the first in the world to be offered direct acting antiviral (DAA) tablets for hepatitis C, as part of National Health Service (NHS) plans to eradicate the disease entirely. 24 August 2021